Bitcoin price today: tumbles below $90k as Fed cut doubts spark risk-off mood
Investing.com -- Solid Biosciences Inc. (NASDAQ:SLDB) stock rose 6.1% on Monday after the company announced a non-exclusive worldwide license agreement with Andelyn Biosciences for its proprietary next-generation capsid, AAV-SLB101.
The agreement allows Andelyn, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), to provide its clients access to Solid’s AAV-SLB101 capsid in combination with Andelyn’s AAV Curator Platform. Financial terms of the deal were not disclosed.
AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle and cardiac tropism with reduced liver biodistribution. According to the company, the capsid has been generally well tolerated in 23 pediatric participants dosed in Solid’s Phase 1/2 INSPIRE DUCHENNE clinical trial as of October 31, 2025.
"This collaboration reflects our shared mission to accelerate the next generation of gene therapies built upon cutting-edge technologies designed to enhance safety and efficacy," said Bo Cumbo, President and CEO of Solid Biosciences. "With more than 30 agreements and licenses already in place for the use of AAV-SLB101, we expect our partnership with Andelyn to help trailblaze a brighter future for gene therapy."
The company noted that robust cardiac and skeletal muscle transduction and biodistribution have been demonstrated in preclinical studies and early clinical data from the INSPIRE DUCHENNE trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.